

TRANSMITTAL LETTER			Case No. 11279/3
Serial No. 10/030,485	Filing Date October 22, 2001	Examiner Unknown	Group Art Unit 1614
Inventor(s) Mira et al.			
Title of Invention NEURONAL EXOCYTOSIS INHIBITING PEPTIDES AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID PEPTIDES			

RECEIVED
MAY 22 2003
TECH CENTER 1600/2900

O I P E
JOY
MAY 20 2003
PATENT & TRADEMARK

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is Transmittal Letter (in dup.); Information Disclosure Statement with attached PTO Form 1449 (in dup.); 3 References; and postcard evidencing receipt.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ Applicant claims small entity status. See 37 CFR 1.27.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

					Small Entity		Other Than Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	Rate	Add'l Fee
Total		Minus			x \$9 =		x \$18 =	
Indep.		Minus			x 42 =		x \$84 =	
First Presentation of Multiple Dep. Claim					+ \$140 =		+ \$280 =	
					Total add'l fee	\$	Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ _____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


Heidi A. Dare
Heidi A. Dare
Registration No. 50,775
Attorney for Applicant
Customer No. 00757 - Brinks Hofer Gilson Lione

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 16, 2003.

Date: May 16, 2003

Signature: *Heidi A. Dare*



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 16, 2003

Date of Deposit

Heidi A. Dare, Reg. No. 50,775

Name of Applicant, Assignee or
Registered Representative

Signature

May 16, 2003

Date of Signature

IDS #9
RECEIVED
6-3-03
MAY 22 2003
TECH CENTER 1600/2500

Our Case No.: 11279/3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mira, et al.

Serial No.: 10/030,485

Filing Date: October 22, 2001

For: NEURONAL EXOCYTOSIS
INHIBITING PEPTIDES AND
COSMETIC AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
SAID PEPTIDES

Examiner: Unknown

Group Art Unit No.: 1614

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents

listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

FOREIGN PATENT DOCUMENTS

No.	Date	Name	Country and PCT No.
WO 97/34620	September 25, 1997	Montal	PCT/US97/04393

OTHER ART DOCUMENTS

No.	Title and Author
A2	Gutierrez, L.M., et al., " <i>A Peptide that Mimics the C-terminal Sequence of SNAP-25 Inhibits Secretory Vesicle Docking in Chromaffin Cells,</i> " The Journal of Biological Chemistry, Vol. 272, No. 5, 31 January 1997, (31.01.97), pages 2634-2639, the whole document, also available on line at http://www-jbc.stanford.edu/jbc/
A3	Oyler, G.A. et al., " <i>The identification of a Novel Synaptosomal-Associated Protein, SNAP-25, Differentially Expressed by Neuronal Subpopulations,</i> " The Journal of Cell Biology, Vol. 109, No. 6, December 1989 (12.89), pages 3039-3052, the whole document.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).


This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks

Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicant(s) hereby certify that each item of the information disclosed in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to filing of the present statement, as evidenced by the date of the enclosed search report.


Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in cursive script, reading "Heidi A. Dare", written over a horizontal line.

Heidi A. Dare
Registration No. 50,775
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200



FORM PTO-1449	SERIAL NO. 10/030,485	CASE NO. 11279/3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE October 22, 2001	GROUP ART UNIT 1614
APPLICANT(S): Mira, et al.		

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	NAME	CLASS/ SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
	A1 WO 97/34620	9-25-1997	PCT	IPC7, C07k, A61K	Yes

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	
	A2	Gutierrez, L.M., et al., "A Peptide that Mimics the C-terminal Sequence of SNAP-25 Inhibits Secretary Vesicle Docking in Chromaffin Cells," The Journal of Biological Chemistry, Vol. 272, No. 5, 31 January 1997, (31.01.97), pages 2634-2639, the whole document, also available on line at http://www-jbc.stanford.edu/jbc/
	A3	Oyler, G.A. et al., "The identification of a Novel Synaptosomal-Associated Protein, SNAP-25, Differentially Expressed by Neuronal Subpopulations," The Journal of Cell Biology, Vol. 109, No. 6, December 1989 (12.89), pages 3039-3052, the whole document

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.